HARBOUR CENTRE (00051) announced its interim results, reporting a loss attributable to shareholders of HKD 82 million, a year-on-year decrease of 58.79%.
Habor Enterprises (00051) announced its interim results for the six months ending June 30, 2026, reporting revenue of HK$705 million, an increase of 7.8% year-on-year; the company attributable loss was HK$82 million, a decrease of 58.79% year-on-year; loss per share was HK$0.12.
HARBOUR CENTRE (00051) announced its interim results for the six months ending June 30, 2026, reporting revenue of HKD 705 million, a year-on-year increase of 7.8%; the loss attributable to shareholders was HKD 82 million, a decrease of 58.79% compared to the previous year; the loss per share was HKD 0.12.
With sustained domestic tourism demand and a series of large local events, the stable recovery trend of Hong Kong's hotel and tourism industry is expected to continue into the second half of 2026. However, developments in the global economy and geopolitical situation may affect consumer confidence and spending patterns, making the overall operating environment highly sensitive to external uncertainties.
On the mainland, domestic tourism demand continues to grow, and the market outlook is promising. However, despite stable fundamental demand, increasing price sensitivity among travelers, the emergence of new hotel supply, and intense competition may place ongoing pressure on room rates and profitability.
In response to the above situation, the group will continue to focus on strictly implementing core strategies, including enhancing operational efficiency, improving service standards, and actively managing the asset portfolio. We will promote targeted initiatives to consolidate our market position and seize new opportunities.
Related Articles

AI empowers the upgrade of early screening and treatment for lung cancer. Domestic medical company Siasun Robot & Automation accelerates the implementation of precise healthcare. Zhenjiankang Medical (02697) seizes industry development opportunities.

NISSIN FOODS (01475): Nissin's first quarter revenue for its China business segment was 18.994 billion yen, an increase of 13.8% year-on-year.

SHUI ON LAND (00272): Holders of $429 million in notes have submitted valid consents to the issuer.
AI empowers the upgrade of early screening and treatment for lung cancer. Domestic medical company Siasun Robot & Automation accelerates the implementation of precise healthcare. Zhenjiankang Medical (02697) seizes industry development opportunities.

NISSIN FOODS (01475): Nissin's first quarter revenue for its China business segment was 18.994 billion yen, an increase of 13.8% year-on-year.

SHUI ON LAND (00272): Holders of $429 million in notes have submitted valid consents to the issuer.

RECOMMEND





